[go: up one dir, main page]

AR096686A1 - Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx - Google Patents

Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx

Info

Publication number
AR096686A1
AR096686A1 ARP140102351A ARP140102351A AR096686A1 AR 096686 A1 AR096686 A1 AR 096686A1 AR P140102351 A ARP140102351 A AR P140102351A AR P140102351 A ARP140102351 A AR P140102351A AR 096686 A1 AR096686 A1 AR 096686A1
Authority
AR
Argentina
Prior art keywords
difluoroetil
espiro
heptano
alx
oxazol
Prior art date
Application number
ARP140102351A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR096686A1 publication Critical patent/AR096686A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol de fórmula (1), en donde los sustituyentes en el anillo piperidina están en disposición trans, a su preparación y a su uso como compuestos farmacéuticamente activos.
ARP140102351A 2013-06-25 2014-06-23 Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx AR096686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2013055220 2013-06-25

Publications (1)

Publication Number Publication Date
AR096686A1 true AR096686A1 (es) 2016-01-27

Family

ID=50981531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102351A AR096686A1 (es) 2013-06-25 2014-06-23 Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx

Country Status (14)

Country Link
US (1) US9676761B2 (es)
EP (1) EP3013817B1 (es)
JP (1) JP6407268B2 (es)
KR (1) KR20160022913A (es)
CN (1) CN105339367B (es)
AR (1) AR096686A1 (es)
AU (1) AU2014301250B2 (es)
BR (1) BR112015032144A8 (es)
CA (1) CA2914917A1 (es)
ES (1) ES2634693T3 (es)
MX (1) MX2015017541A (es)
RU (1) RU2016102059A (es)
TW (1) TW201536286A (es)
WO (1) WO2014206966A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
MA39972B1 (fr) 2014-05-13 2024-10-31 Novartis Ag Composés et compositions d'induction de la chondrogenèse
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
BR112017024966A2 (pt) 2015-05-27 2018-08-07 Kyorin Seiyaku Kk derivado de ureia ou sal farmacologicamente aceitável do mesmo

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002587A1 (en) 1993-07-16 1995-01-26 Merck & Co., Inc. Substituted piperazinylcamphor derivatives as oxytocin antagonists
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
JP2007516434A (ja) 2003-11-07 2007-06-21 アカディア ファーマシューティカルズ インコーポレイティド リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
JP4656674B2 (ja) 2007-12-18 2011-03-23 アクテリオン ファーマシューティカルズ リミテッド アミノトリアゾール誘導体
NZ597122A (en) * 2009-05-18 2013-06-28 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
RU2544862C2 (ru) 2009-06-09 2015-03-20 Актелион Фармасьютиклз Лтд Фторированные аминотриазольные производные
JP5624130B2 (ja) 2009-06-12 2014-11-12 アクテリオンファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのオキサゾール及びチアゾール誘導体
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CA2814826C (en) * 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
AU2011340103A1 (en) 2010-12-07 2013-07-25 Actelion Pharmaceuticals Ltd. Hydroxylated aminotriazole derivatives as ALX receptor agonists
CN103261194B (zh) 2010-12-07 2016-02-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑基-甲醚衍生物
WO2013009543A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
CA2871334A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN105007908B (zh) 2013-03-06 2017-10-03 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
SG11201507113RA (en) 2013-03-06 2015-10-29 Allergan Inc Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx

Also Published As

Publication number Publication date
BR112015032144A2 (pt) 2017-07-25
JP2016523873A (ja) 2016-08-12
AU2014301250A1 (en) 2016-02-11
ES2634693T3 (es) 2017-09-28
AU2014301250B2 (en) 2018-07-12
KR20160022913A (ko) 2016-03-02
CA2914917A1 (en) 2014-12-31
CN105339367A (zh) 2016-02-17
JP6407268B2 (ja) 2018-10-17
WO2014206966A1 (en) 2014-12-31
US20160289221A1 (en) 2016-10-06
MX2015017541A (es) 2016-04-26
BR112015032144A8 (pt) 2017-12-26
US9676761B2 (en) 2017-06-13
RU2016102059A (ru) 2017-07-28
EP3013817A1 (en) 2016-05-04
TW201536286A (zh) 2015-10-01
CN105339367B (zh) 2018-04-17
EP3013817B1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY35409A (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
UY35408A (es) 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
UY35639A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR096686A1 (es) Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
MX373855B (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
CO2018011231A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2
MX2016000731A (es) Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.
DOP2015000271A (es) Derivados de imidazo-triazina como inhibidores de pde10
UY37386A (es) Compuestos de tiopicolinamida con actividad antifúngica
CL2018003188A1 (es) Procedimiento para la preparación de cuerpos moldeados para la administración a animales.
CR20150530A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Legal Events

Date Code Title Description
FB Suspension of granting procedure